Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...

Parkinson’s disease is a progressive neurodegenerative disorder that affects millions of people worldwide. In the United ...

Combining levodopa with a DDC inhibitor (DDCI), such as carbidopa or benserazide, greatly reduces the incidence of nausea and vomiting, increases the levodopa half-life from approximately 60 to 90 ...

In an analysis of health data from 130million people, British researchers found medications which could potentially increase, or decrease, the risk that someone could be diagnosed with dementia.

Nat Clin Pract Gastroenterol Hepatol. 2007;4(5):236-237. Now that the idea that hepatic fibrosis is reversible is taking root, many clinicians are beginning to ask why, if fibrosis is ...

76 Figure 4: Comparison of pharmacokinetic profiles of levodopa–carbidopa administered at 3-hour intervals with and without the catechol-O-methyltransferase inhibitor entacapone. 81 On the basis ...